BreachRx

About BreachRx

BreachRx operates in the cybersecurity sector, offering an intelligent incident response platform designed to provide operational resilience for the entire enterprise. Founded in 2017 by CEO Andy Lunsford and CPO Matt Hartley, the company aims to replace chaotic, manual incident response processes with a coordinated, automated, and compliant approach. Lunsford's background in privacy law and commercial litigation, combined with Hartley's two decades in cybersecurity and threat intelligence, including time in the U.S. Air Force, shaped the company's vision to address the fragmented and high-pressure nature of responding to cyber threats.

The company's core offering is a SaaS-based platform that brings order to the periods before, during, and after a security incident. It automates the generation of tailored incident response plans based on constantly changing global regulations, ensuring that all stakeholders—from security and legal to communications and executive leadership—have clear, role-based guidance and defined timelines. Key features include a secure, centralized workspace for cross-functional collaboration, integrated privileged communication channels to protect legal discussions, and comprehensive audit trails to ensure defensibility for regulators and auditors. Recently, the company introduced Rex AI, a generative AI engine to further streamline processes by providing real-time recommendations and generating reports.

BreachRx's business model is centered on its software platform, serving a client base that includes over 100 customers, among them publicly traded and Fortune 500 companies in critical sectors like financial services, technology, healthcare, and retail. The company has demonstrated significant traction, achieving over 3x year-over-year annual recurring revenue (ARR) growth for two consecutive years. The firm generates revenue by selling its platform to enterprises and also engages with a network of partners, including legal firms, MSSPs, and compliance consultants, to expand its reach. After launching in 2020, BreachRx has secured over $23 million in total funding across three rounds, culminating in a $15 million Series A in May 2025 led by Ballistic Ventures.